MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Cellectar Biosciences Inc

Închisă

0.28 -3.45

Rezumat

Modificarea prețului

24h

Curent

Minim

0.28

Maxim

0.3

Indicatori cheie

By Trading Economics

Angajați

11

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+244.83% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

2.2M

16M

Deschiderea anterioară

3.73

Închiderea anterioară

0.28

Cellectar Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 dec. 2024, 18:44 UTC

Principalele dinamici ale pieței

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Comparație

Modificare preț

Cellectar Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

244.83% sus

Prognoză pe 12 luni

Medie 1 USD  244.83%

Maxim 1 USD

Minim 1 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCellectar Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

$

Despre Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.